TY - JOUR
T1 - New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases
AU - Ferrer, Jennifer R.
AU - Chokechanachaisakul, Attasit
AU - Wertheim, Jason A.
N1 - Funding Information:
We thank the support of the Zell Family Foundation. J.R.F. acknowledges support from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM105538. J.A.W. acknowledges support from the Robert R. McCormick Foundation, American Association for the Study of Liver Diseases and the American Liver Foundation’s Liver Scholar Award, Society for Surgery for the Alimentary Tract’s Career Development Award, and NIDDK K08DK10175. This work was supported in part by Health Resources and Services Administration contract 234-2005-37011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Funding Information:
We thank the support of the Zell Family Foundation. J.R.F. acknowledges support from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM105538. J.A.W. acknowledges support from the Robert R. McCormick Foundation, American Association for the Study of Liver Diseases and the American Liver Foundation?s Liver Scholar Award, Society for Surgery for the Alimentary Tract?s Career Development Award, and NIDDK K08DK10175. This work was supported in part by Health Resources and Services Administration contract 234-2005-37011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. ? Jennifer R. Ferrer and Attasit Chokechanachaisakul declare that they have no conflict of interest. Jason A. Wertheim reports non-financial support from Cellular Dynamics International, unrelated to the preparation of this manuscript. This article does not contain any studies with human or animal subjects performed by any of the authors.
Publisher Copyright:
© 2015, Springer International Publishing AG.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The current standard of care for end stage liver disease is orthotopic liver transplantation (OLT). Through improvement in surgical techniques, immunosuppression, and general medical care, liver transplantation has become an effective treatment over the course of the last half-century. Unfortunately, due to the limited availability of donor organs, there is a finite limit to the number of patients who will benefit from this therapy. This review will discuss current research in experimental cellular therapies for acute, chronic, and metabolic liver failure that may be appropriate when liver transplantation is not an immediate option.
AB - The current standard of care for end stage liver disease is orthotopic liver transplantation (OLT). Through improvement in surgical techniques, immunosuppression, and general medical care, liver transplantation has become an effective treatment over the course of the last half-century. Unfortunately, due to the limited availability of donor organs, there is a finite limit to the number of patients who will benefit from this therapy. This review will discuss current research in experimental cellular therapies for acute, chronic, and metabolic liver failure that may be appropriate when liver transplantation is not an immediate option.
KW - Alternative cell sources
KW - Cellular therapy
KW - Hepatocyte transplantation
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=84962933421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962933421&partnerID=8YFLogxK
U2 - 10.1007/s40472-015-0059-4
DO - 10.1007/s40472-015-0059-4
M3 - Article
AN - SCOPUS:84962933421
VL - 2
SP - 202
EP - 210
JO - Current Transplantation Reports
JF - Current Transplantation Reports
SN - 2196-3029
IS - 2
ER -